Novonesis delivered strong organic sales growth of 7% in 2025
MWN-AI** Summary
Novonesis, the pure biosolutions company based in Copenhagen, showcased impressive organic sales growth of 7% for the year 2025. This performance was complemented by an adjusted EBITDA margin of 37.1%, reflecting strong cash flow generation despite currency challenges. Ester Baiget, the President and CEO, emphasized the broad-based growth across various sales areas and markets, particularly noting the robust performance in Emerging Markets which grew by 9%.
In their financial highlights, Novonesis reported a solid foundation for future growth, with Food & Health segments achieving an 8% increase in organic sales, and the Planetary Health sector also contributing positively with a 6% growth. The company managed to navigate disruptions from exiting certain markets which had a minor negative impact on growth metrics.
Financially, Novonesis showed resilience, maintaining a strong adjusted EBITDA margin and achieving an adjusted net profit increase of 17%. The company declared a proposed dividend of DKK 4.25 per share, reflecting an overall pay-out ratio of 58.4% of adjusted net profit. Their focus on innovation was evident, with 33 new product launches in 2025, which contributed to 25% of total sales.
Looking forward to 2026, Novonesis anticipates continued organic sales growth between 5-7%. The outlook also suggests an adjusted EBITDA margin between 37-38%, indicating potential margin expansion despite currency headwinds. Baiget remains optimistic about the company's strategy and performance, setting a resilient tone for the future as Novonesis aims to accomplish its ambitious targets for 2030 and beyond.
MWN-AI** Analysis
Novonesis's recent performance highlights its resilience and strategic growth, presenting a compelling case for market optimism. With a substantial 7% organic sales growth in 2025 and an impressive adjusted EBITDA margin of 37.1%, the company's trajectory appears robust. Positive indicators include broad-based growth, particularly in Emerging Markets where the organic sales surged by 9%. This suggests that Novonesis possesses the agility to adapt and thrive, even amid challenges like currency headwinds and exits from certain countries.
The company’s focus on innovation, underscored by 33 new product launches in 2025 and a significant contribution of 25% to sales from innovations over the last five years, amplifies its competitive edge. Investors should take note of Novonesis's strategic positioning as a biosolutions leader, which is likely to further drive performance and mitigate risks associated with market volatility. The expected organic sales growth range of 5-7% and anticipated margin expansion in 2026 suggests continued operational efficiency and profitability.
However, the forecast includes a caveat of potential lower consumer sentiment, a factor that could impact growth. Therefore, while the near-term outlook is promising, investors should remain attuned to macroeconomic trends and consumer behavior shifts that may influence performance.
As for the dividend component, Novonesis's proposed payout of DKK 4.25 per share and a pay-out ratio of 58.4% reflects a commitment to returning value to shareholders, reinforcing its attractiveness as a long-term investment.
Given Novonesis's strong fundamentals and strategic foresight, coupled with innovative growth prospects, this stock appears to be a promising addition for those looking to capitalize on the growing biosolutions sector. Investors should consider entering or increasing their position, keeping in mind market conditions and consumer sentiment trends.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
COPENHAGEN, Denmark – February 26, 2026. Novonesis delivered strong organic sales growth of 7% and an adjusted EBITDA margin of 37.1% in 2025. The company expects a good start to 2026 and a good year overall.
Ester Baiget, President & CEO:
“In 2025, we continued to deliver strong organic sales growth. We achieved 7% growth, an adjusted EBITDA margin of 37.1% and a strong cash flow – despite currency headwinds. Growth was broad-based across sales areas and markets, with particularly strong performance in Emerging Markets. As a pure biosolutions player, Novonesis uniquely combines deep understanding of customers, innovation leadership and world-class scale capabilities, driving performance and strengthening resilience. In 2026, we expect another good year, with growth across all sales areas and margin expansion. We continue to execute on our strategy, positioning us to firmly deliver on our 2030 targets and beyond."
Highlights of our full-year 2025 results:
• Broad-based organic sales growth of 7% (Q4: 4%) including the negative impact of exiting certain countries of ~1%-point (Q4: ~2%-points). Price contributed ~1%-point (Q4: ~1%-point) and sales synergies contributed ~1%-point (Q4: ~1%-point).
• Food & Health at 8% organic sales growth (Q4: 7%) including the negative impact of exiting certain countries of ~3%-points (Q4: ~5%-
points). Planetary Health at 6% organic sales growth (Q4: 2%, including double-digit growth in Energy).
• Emerging Markets grew 9% organically (Q4: 1%) including the exit from certain countries. Developed Markets grew 6% organically (Q4: 6%).
• Adjusted EBITDA margin at 37.1% (Q4: 36.6%), up by 100 bps (Q4: up by 40 bps) including one-off expenses in Q4 and currency headwinds
for both the quarter and the year. Adjusted gross margin at 59.1% (Q4: 59.9%) up by 240bps (Q4: up by 250bps).
• Adjusted net profit increased by 17% (Q4: flat).
• NIBD/EBITDA at 1.9x, and free cash flow before acquisitions at EUR 770.4 million, or 19% of sales.
• Proposed dividend of DKK 4.25/share. DKK 2.25/share interim dividend paid Aug. 27, 2025. 2025 pay-out ratio of 58.4% of adj. net profit.
• 33 new product launches in 2025 (Q4: 14). New innovations launched over the last 5 years made up 25% of sales.
• Achievement of all six environmental and social targets for 2025 and on track for future commitments.
• 2026 outlook: Organic sales growth between 5-7% with a good start to the year expected against a strong 2025 comparable. The outlook includes some uncertainty of potential lower consumer sentiment for the year. The outlook also includes ~1%-point from positive pricing and ~1%-point from sales synergies as well as close to 1%-point negative impact from exiting certain countries. The outlook for the
adjusted EBITDA margin is between 37-38% with an expected margin expansion, including currency headwinds of ~50 bps vs 2025.
Here is the link to the investor call on Novonesis full-year results for 2025: Novonesis Full-year financial statement for 2025 and annual report 2025
Get in touch
Line Fedders
Senior Media Relation Manager
media-relations@novonesis.com
+45 30 77 13 99
Tobias Bjorklund
Head of Investor Relations
Attachment
FAQ**
How does Novonesis AS - Class B NVZMF plan to address the potential challenges of lower consumer sentiment mentioned in the 2026 outlook?
With a proposed dividend of DKK 4.25/share, how does Novonesis AS - Class B NVZMF ensure that it maintains a balanced pay-out ratio while funding growth initiatives?
What specific strategies will Novonesis AS - Class B NVZMF employ to achieve its targeted organic sales growth of 5-7% in 2026 amidst uncertainties?
Can you provide insights into how the 33 new product launches in 2025 will impact Novonesis AS - Class B NVZMF's performance in the Emerging Markets segment?
**MWN-AI FAQ is based on asking OpenAI questions about Novonesis AS - Class B (OTC: NVZMF).
NASDAQ: NVZMF
NVZMF Trading
-0.48% G/L:
$55.285 Last:
513 Volume:
$56.74 Open:
